IIM
TBPH

INTECH Investment Management’s Theravance Biopharma TBPH Stock Holding History

INTECH Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
12,089
-1,577
-12% -$26.1K ﹤0.01% 1783
2026
Q1 		$222K Sell
13,666
-6,778
-33% -$120K ﹤0.01% 1703
2025
Q4 		$383K Sell
20,444
-2,232
-10% -$37K ﹤0.01% 1635
2025
Q3 		$331K Sell
22,676
-4,014
-15% -$50.7K ﹤0.01% 1784
2025
Q2 		$294K Sell
26,690
-6,597
-20% -$64.1K ﹤0.01% 1868
2025
Q1 		$297K Buy
33,287
+10,352
+45% +$96.3K ﹤0.01% 1895
2024
Q4 		$216K Buy
+22,935
New +$209K ﹤0.01% 1997

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

INTECH Investment Management's TBPH Position: Q2 2026 in Review

INTECH Investment Management reduced its Theravance Biopharma (TBPH) stake by 12% in Q2 2026, selling an estimated $26.1K and leaving 12,089 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #1783.

INTECH Investment Management first reported a position in TBPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $383K in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • INTECH Investment Management held 12,089 shares of Theravance Biopharma worth $206K as of Q2 2026.
  • INTECH Investment Management sold 1,577 Theravance Biopharma shares in Q2 2026, an estimated $26.1K.
  • Theravance Biopharma made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1783 holding.
  • INTECH Investment Management first reported a position in Theravance Biopharma in Q4 2024 and has held it in 7 quarters since.
  • INTECH Investment Management's Theravance Biopharma position peaked at $383K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.